The unit weight of municipal solid waste is a critical parameter in engineering analyses of landfills execution, design, and stability of landfills, but significant uncertainty as of now exists with respect to its value. By using synthetic municipal solid waste (SMSW) that replicates the typical composition of waste produced in India. To determine the relation between Maximum Dry Density (MDD) & Optimum Moisture Content (OMC) of fresh SMSW "Modified Proctor Test" has been performed. MSW is a very heterogeneous material, numerous efforts have been made in the past to generalize the density of MSW, but still, the effect of each material on the density is Obscure. In this paper, the variation in MDD & OMC has been provided depending on the varying percentage of each material (Paper, Plastic & Organic Content) present in it. As a result of regulations and shifting consumer habits, waste is continually changing. Engineers must therefore be mindful of the evolving mechanical characteristics of trash, and it's possible that prior findings may not be a reliable indicator of how waste will behave in the future. Therefore, Calculating the variation in unit weight can be useful in designing engineered MSW landfills and for future references.

IntroductionAs the rates of age-related macular denegation exponentially increase, new innovation is required to address the challenges faced by our ageing population. The aim of the Palmerston North Interventional Rapid Avastin Treat and Extend (PIRATE) study is to establish the safety and efficacy of rapid treatment extension of bevacizumab (Avastin) in patients with low-risk neovascular age-related macular degeneration (nAMD).Methods and analysisThe PIRATE study is a monocentric, non-blinded, open-label randomised control trial. Participants over the age of 50 years with low-risk nAMD characteristics will be recruited in a prospective manner and randomised into treatment and control groups. Rapid treatment extension by 4 weeks will be applied in the treatment group, with the standard 2-week treatment extension occurring among controls. Participants will enter the trial after initial treatment induction consisting of three bevacizumab injections, 1 month apart. The primary outcome of best-corrected visual acuity will be assessed along with predetermined secondary outcomes at a study duration of 12 months (initial) and 24 months (total).Trial registration numberACTRN12622001246774p.

No abstract

No abstract

No abstract